| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Total Assets  | 475 | 625 | 764 | 916 | 1,091 | 1,374 | 1,661 | 2,347 | 2,386 | 2,456 | 2,717 |
| Fixed Assets | 150 | 166 | 190 | 208 | 209 | 413 | 447 | 1,369 | 1,305 | 1,228 | 1,168 |
| Current Assets | 282 | 424 | 511 | 623 | 814 | 893 | 1,145 | 875 | 973 | 1,127 | 1,364 |
| Capital Work in Progress | 1 | 4 | 18 | 10 | 3 | 11 | 10 | 15 | 5 | 6 | 4 |
| Investments | 38 | 64 | 105 | 145 | 185 | 164 | 59 | 66 | 150 | 114 | 327 |
| Other Assets | 286 | 391 | 452 | 554 | 694 | 786 | 1,145 | 898 | 926 | 1,109 | 1,218 |
| Total Liabilities | 475 | 625 | 764 | 916 | 1,091 | 1,374 | 1,661 | 2,347 | 2,386 | 2,456 | 2,717 |
| Current Liabilities | 112 | 91 | 74 | 116 | 138 | 227 | 274 | 500 | 470 | 464 | 402 |
| Non Current Liabilities | 20 | 24 | 28 | 8 | 1 | 93 | 111 | 310 | 216 | 107 | 108 |
| Total Equity | 343 | 510 | 662 | 792 | 951 | 1,054 | 1,276 | 1,537 | 1,700 | 1,885 | 2,207 |
| Reserve & Surplus | 260 | 424 | 577 | 734 | 890 | 974 | 1,162 | 1,418 | 1,583 | 1,766 | 2,089 |
| Share Capital | 81 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 84 | 84 |
Dr. Lal Path Labs
2,880.00
+25.30
(0.89%)
Market Cap
24,127.35 Cr
EPS
58.48
PE Ratio
48.92
Dividend Yield
0.84 %
Industry
Healthcare Services52 Week High
3,653.95
52 Week Low
2,293.55
PB Ratio
11.00
Debt to Equity
0.10
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from21 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
2,880.00 | #1 24,127.35 | #5 48.92 | #1 2,554.80 | #7 11.28 | #1 492 | #2 81.24 | 53.16 | |
1,002.00 | 10,289.25 | 72.14 | 681.39 | 20.11 | 152 | 3.56 | 65.15 | |
1,866.00 | 9,666.23 | 66.39 | 1,331.20 | 4.59 | 142 | -20.00 | 63.94 | |
1,068.40 | 5,661.93 | 62.26 | 687.35 | 8.63 | 98 | 25.58 | 58.44 | |
779.45 | 2,516.83 | 30.79 | 717.16 | 25.65 | 81 | 10.70 | 59.17 | |
320.20 | 1,667.63 | 52.91 | 252.09 | 14.77 | 31 | 14.29 | 47.92 | |
1,599.00 | 1,372.36 | 29.06 | 96.47 | 25.47 | 49 | -9.09 | 53.43 | |
280.05 | 890.85 | #1 9.47 | 1,110.95 | 35.04 | -197 | -18.52 | 50.46 | |
280.10 | 547.39 | 28.63 | 147.04 | #1 248.07 | 18 | #1 175.00 | 54.82 | |
182.00 | 126.75 | 83.40 | 41.78 | 6.34 | 1 | 28.57 | 66.97 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
11.28 %
Net Income Growth
35.88 %
Cash Flow Change
6.27 %
ROE
16.08 %
ROCE
4.17 %
EBITDA Margin (Avg.)
4.50 %
Balance Sheet
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 8 | -5 | 2 | 37 | 64 | 67 | 48 | 134 | -115 | 97 | -68 |
| Investing Activities | -114 | -164 | -137 | -172 | -100 | -26 | -212 | -449 | -287 | -24 | -303 |
| Operating Activities | 122 | 159 | 171 | 197 | 219 | 284 | 398 | 447 | 456 | 535 | 569 |
| Financing Activities | -1 | 0 | -32 | 13 | -55 | -190 | -139 | 136 | -283 | -414 | -334 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 55.23 % | 55.23 % | 55.23 % | 55.23 % | 55.23 % | 55.05 % | 55.05 % | 55.05 % | 55.03 % | 55.01 % | 54.61 % | 54.60 % | 54.60 % | 54.60 % | 53.92 % | 53.91 % | 53.91 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 2.00 % | 1.83 % | 0.00 % | 0.00 % | 0.00 % | 26.15 % | 25.42 % | 26.82 % | 26.82 % | 23.91 % |
| DIIs | 6.47 % | 5.61 % | 4.84 % | 5.58 % | 5.69 % | 5.30 % | 5.09 % | 6.19 % | 6.55 % | 7.33 % | 7.97 % | 8.61 % | 9.69 % | 12.71 % | 12.89 % | 13.17 % | 16.08 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 5.70 % | 6.24 % | 6.93 % | 7.45 % | 9.03 % | 10.44 % | 8.24 % | 9.03 % | 9.50 % | 9.31 % | 8.37 % | 7.26 % | 6.47 % | 4.91 % | 4.10 % | 4.01 % | 4.11 % |
| Others | 32.60 % | 32.92 % | 32.99 % | 31.74 % | 30.05 % | 29.22 % | 31.63 % | 27.73 % | 27.09 % | 28.35 % | 29.05 % | 29.53 % | 3.09 % | 2.35 % | 2.27 % | 2.10 % | 2.00 % |
| No of Share Holders | 68,845 | 94,123 | 1,25,953 | 1,35,068 | 1,71,846 | 1,84,508 | 1,71,602 | 1,79,636 | 1,80,163 | 1,74,444 | 1,60,679 | 1,49,901 | 1,46,741 | 1,31,189 | 1,16,606 | 1,16,236 | 1,15,699 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3 | 4.5 | 6 | 12 | 20 | 12 | 6 | 24 | 24 |
| Dividend Yield (%) | 0.00 | 0.34 | 0.43 | 0.43 | 0.44 | 0.77 | 0.67 | 0.27 | 0.97 | 0.84 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Jun 2025 |  Annual General Meeting | NA | 28 Jun 2025 | 2,906.55 | 2,771.25 |
| 06 Jun 2025 |  Dividend | ₹ 6.00 /share | 06 Jun 2025 | 2,906.55 | 2,846.20 |
| 25 Apr 2025 |  Quarterly Result Announcement | NA | 25 Apr 2025 | 2,714.10 | 2,906.55 |
| 06 Feb 2025 |  Extraordinary General Meeting | NA | 06 Feb 2025 | 2,801.45 | 2,801.45 |
| 05 Feb 2025 | Dividend | ₹ 6.00 /share | 05 Feb 2025 | 2,879.40 | 2,792.50 |
| 30 Jan 2025 | Quarterly Result Announcement | NA | 30 Jan 2025 | 2,877.65 | 2,879.40 |
| 05 Nov 2024 | Dividend | ₹ 6.00 /share | 05 Nov 2024 | 3,252.50 | 3,070.90 |
| 23 Oct 2024 | Quarterly Result Announcement | NA | 23 Oct 2024 | 3,329.85 | 3,252.50 |
| 20 Aug 2024 | Dividend | ₹ 6.00 /share | 20 Aug 2024 | 3,274.60 | 3,341.35 |
| 29 Jun 2024 | Annual General Meeting | NA | 29 Jun 2024 | 2,348.85 | 2,779.70 |
| 10 Jun 2024 | Dividend | ₹ 6.00 /share | 10 Jun 2024 | 2,348.85 | 2,783.80 |
| 13 Feb 2024 | Dividend | ₹ 12.00 /share | 13 Feb 2024 | 2,498.50 | 2,477.10 |
| 11 Aug 2023 | Dividend | ₹ 6.00 /share | 11 Aug 2023 | 2,354.65 | 2,298.00 |
| 11 Aug 2023 | Dividend | ₹ 6.00 /share | 11 Aug 2023 | 1,906.80 | 2,298.00 |
| 09 Aug 2022 | Dividend | ₹ 6.00 /share | 05 Aug 2022 | 2,144.50 | 2,415.45 |
| 23 Jun 2022 | Dividend | ₹ 6.00 /share | 22 Jun 2022 | 2,184.60 | 1,993.80 |
| 22 Aug 2021 | Dividend | ₹ 6.00 /share | 18 Aug 2021 | 3,556.35 | 3,852.65 |
| 22 Jul 2021 | Dividend | ₹ 8.00 /share | 20 Jul 2021 | 2,833.65 | 3,332.95 |
| 10 Feb 2021 | Dividend | ₹ 6.00 /share | 09 Feb 2021 | 2,247.35 | 2,391.40 |
Announcements
Shareholder Meeting / Postal Ballot-Scrutinizers Report
9 days ago
9 days agoShareholder Meeting / Postal Ballot-Outcome of AGM10 days ago
10 days agoClosure of Trading WindowJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 25, 2025
Jun 25, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 05, 2025
Jun 05, 2025Letter Dispatched To The Members Of The Company- Weblink Of The Annual Report FY 2024-25Jun 04, 2025
Jun 04, 2025Business Responsibility and Sustainability Reporting (BRSR)Jun 04, 2025
Jun 04, 202531St Annual General Meeting To Be Held On June 28 2025Jun 04, 2025
Jun 04, 2025Reg. 34 (1) Annual Report.Jun 04, 2025
Jun 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 30, 2025
May 30, 2025Amended Trust DeedMay 19, 2025
May 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2025
May 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 08, 2025
May 08, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 01, 2025
May 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 26, 2025
Apr 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeApr 25, 2025
Apr 25, 2025Announcement under Regulation 30 (LODR)-Investor PresentationApr 25, 2025
Apr 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 25, 2025
Apr 25, 2025Annual General MeetingApr 25, 2025
Apr 25, 2025Appointment Of Auditors Viz. Internal Auditor Cost Auditor And Secretarial AuditorApr 25, 2025
Apr 25, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateApr 25, 2025
Apr 25, 2025Record Date For Final Dividend For The Financial Year Ended March 31 2025Apr 25, 2025
Apr 25, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesApr 25, 2025
Apr 25, 2025Board Meeting Outcome for Outcome Of Board Meeting Dated April 25 2025Apr 25, 2025
Apr 25, 2025Financial Results For The Quarter And Financial Year Ended March 31 2025Apr 25, 2025
Apr 25, 2025Announcement under Regulation 30 (LODR)-Credit RatingApr 22, 2025
Apr 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 21, 2025
Apr 21, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceApr 18, 2025
Apr 18, 2025Board Meeting Intimation for Considering And Approving The Audited Financial Results Of The Company For The Quarter And FY Ended March 31 2025 And To Consider Recommending Final Dividend If AnyApr 18, 2025
Apr 18, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 15, 2025
Apr 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Apr 11, 2025Grant Of Stock OptionsApr 09, 2025
Apr 09, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMar 31, 2025
Mar 31, 2025Closure of Trading WindowMar 25, 2025
Mar 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 20, 2025
Mar 20, 2025Update On Voluntary Liquidation Of Suburban Diagnostics (India) Private Limited (A Wholly Owned Subsidiary Of The Company)Mar 18, 2025
Mar 18, 2025Announcement under Regulation 30 (LODR)-Credit RatingMar 14, 2025
Mar 14, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 18, 2025
Feb 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 08, 2025
Feb 08, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 07, 2025
Feb 07, 2025Update On Voluntary Liquidation Of Suburban Diagnostics (India) Private Limited Wholly Owned SubsidiaryFeb 06, 2025
Feb 06, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 31, 2025
Jan 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 30, 2025
Jan 30, 2025Integrated Filing (Financial)Jan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 30, 2025
Jan 30, 2025Amendment In Code Of Practices And Procedures For Fair Disclosure Of Unpublished Price Sensitive InformationJan 30, 2025
Jan 30, 2025Technical Indicators
RSI(14)
Neutral 53.78
ATR(14)
Less Volatile 69.73
STOCH(9,6)
Neutral 44.84
STOCH RSI(14)
Neutral 56.41
MACD(12,26)
Bearish -2.63
ADX(14)
Weak Trend 18.74
UO(9)
Bearish 48.79
ROC(12)
Downtrend And Accelerating -0.87
WillR(14)
Neutral -40.56
Mutual Fund Holdings
HDFC Flexi Cap Direct Plan-Growth 
Nippon India Pharma Fund Direct-Growth 
SBI Large & Midcap Fund Direct Plan-Growth 
Sundaram Mid Cap Fund Direct-Growth 
PGIM India Midcap Fund Direct-Growth 
Aditya Birla Sun Life Flexi Cap Fund Direct-Growth 
Tata Balanced Advantage Fund Direct - Growth 
NJ Balanced Advantage Fund Direct - Growth 
Canara Robeco Large and Mid Cap Fund Direct-Growth 
Bajaj Finserv Flexi Cap Fund Direct-Growth 
Baroda BNP Paribas Multi Cap Fund Direct-Growth 
Mirae Asset Small Cap Fund Direct-Growth 
Kotak Balanced Advantage Fund Direct - Growth About Dr. Lal Path Labs
Dr Lal PathLabs is a leading diagnostic healthcare service provider in India. The company operates a nationwide network of medical laboratory centers, offering over 5000 diagnostic tests and related healthcare services. Its infrastructure includes a National Reference Laboratory in New Delhi, Regional Reference Labs in Kolkata, Bangalore, and Mumbai, 371 clinical laboratories, 5,102 patient service centers, and 10,938 pickup points as of March 31, 2023. The company provides services to individual patients, hospitals, healthcare providers, and corporate customers. Its test catalog includes 481 test panels, 2763 pathology tests, and 1947 radiology and cardiology tests. Dr Lal PathLabs has expanded through acquisitions and has several domestic and international subsidiaries. The company continues to grow its network and enhance its technological capabilities to improve its diagnostic services.
Listing Date
23 Dec, 2015(9 Years,
15 days)
Website
Chairperson NameArvind Lal
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
